Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Myriad Genetics Shares Got Crushed Today

By Maxx Chatsko - Nov 5, 2019 at 2:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic-testing leader just whacked its fiscal full-year 2020 guidance.

What happened

Shares of Myriad Genetics (MYGN 2.91%) fell over 42% today after the company reported fiscal first-quarter 2020 operating results. The latest numbers make it clear that the genetic testing pioneer continues to struggle, which is all the more surprising considering peers and competitors are making double-digit growth look ridiculously easy.

Not so for Myriad Genetics. A change in billing codes commonly used for its hereditary cancer tests, originally expected to have an immaterial impact on the business in fiscal 2020, is now expected to lead to a significant reduction in revenue and earnings. Management told investors to expect improvements as the company transitions into fiscal 2021, but that's not what weary shareholders want to hear after just one quarter of operations in the current fiscal year.

As of 1:12 p.m. EST on Tuesday, the stock had settled to a 41.5% loss. 

An angry fist pounding a table as a declining stock chart displays on a tablet.

Image source: Getty Images.

So what

Citing the deletion of a commonly used billing code, Myriad Genetics reduced fiscal full-year 2020 revenue guidance from its original estimate of $870 million to a new expectation of just $805 million. Wall Street analysts on average were once expecting $922 million, which dropped to $872 million after the company issued its original guidance. It appears analysts will need to significantly alter expectations yet again.

That lost revenue will severely hurt the profitability of the business, as summarized by the table below:

Metric, Fiscal Full-Year 2020

Myriad Genetics Original Guidance

Myriad Genetics New Guidance

Wall Street Original Estimate

Wall Street Latest Estimate

Total revenue

$865 million to $875 million

$800 million to $810 million

$922 million

$872 million

Adjusted earnings per share 

$1.80 to $1.90

$1.00 to $1.10

$1.92

$1.82

Data source: Myriad, Yahoo! Finance.

For additional context, Myriad now expects to generate less revenue and adjusted EPS in the current fiscal year than the previous year. In fiscal 2019, the business generated $851 million in sales and $1.42 in adjusted earnings. 

Now what

Disappointing news is becoming normal for Myriad Genetics. It has failed to generate much momentum in recent years or to adequately replace shrinking revenue from its legacy hereditary cancer portfolio with new genetic tests in other areas, such as prenatal or for prostate cancer. This quarterly report is just the latest example of how the pioneering company has lost its way. Judging from today's stock move, investors may have finally run out of patience.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$22.65 (2.91%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.